Illinois General Assembly - Full Text of HR0981
Illinois General Assembly

Previous General Assemblies

Full Text of HR0981  102nd General Assembly




HR0981LRB102 29409 MST 41402 r


2    WHEREAS, The Illinois Department of Public Health's May
32022 report recorded 3,013 fatalities that occurred in 2021
4due to opioid overdoses; and
5    WHEREAS, The 3,013 Illinois opioid overdose deaths
6represent a 2.3% increase from 2020 and a 35.8% spike from
72019; and
8    WHEREAS, In 2021, toxicology testing found that 2,672
9(89%) of the opioid fatalities involved a synthetic opioid,
10such as fentanyl; and
11    WHEREAS, A 4 mg naloxone hydrochloride nasal spray has
12been the principal tool used by bystanders and emergency
13medical services (EMS) to revive an individual from an
14overdose episode; and
15    WHEREAS, A study, published in the Harm Reduction Journal
16in May 2022, surveyed 125 adult U.S. residents who had been
17administered 4 mg Naloxone nasal spray during an opioid
18overdose and found that 78% used 2 or more doses and 30% used 3
19or more doses of Naloxone; and
20    WHEREAS, A 2021 Johns Hopkins Bloomberg School of Public



HR0981- 2 -LRB102 29409 MST 41402 r

1Health study published in the Harm Reduction Journal reported
2on a survey of 171 people who use opioids in suburban Maryland;
3sixty-one (35.7%) of these people who use opioids had received
4take-home naloxone over a six month period: 57% of naloxone
5recipients used it to reverse an overdose; 79% of overdose
6reversals reported needing more than 2 doses; and
7    WHEREAS, Published by the National Library of Medicine, a
8study of the National Emergency Medical Services Information
9System Database of more than 10,000 EMS agencies across 47
10states with 946,000 calls giving Naloxone shows that use of
11Naloxone multi-dosing by EMS increased 54% over five-years,
12from 18.4% to 28.4% in 2020; and
13    WHEREAS, On April 30, 2021, the U.S. Food and Drug
14Administration approved a higher 8 milligram dose of naloxone
15hydrochloride nasal spray product to treat opioid overdose;
17    WHEREAS, Thirty-four U.S. States have open access to the 8
18mg naloxone nasal spray on their Naloxone Standing Orders,
19including Ohio, Kentucky, Iowa, Pennsylvania, Massachusetts,
20New Jersey, Virginia, Alabama, Florida, Tennessee, Colorado,
21Alaska, New Hampshire, Illinois, Arizona, Kansas, California,
22Texas, Georgia, South Carolina, North Carolina, West Virginia,
23Michigan, Connecticut, Oklahoma, Minnesota, Maine, Louisiana,



HR0981- 3 -LRB102 29409 MST 41402 r

1Nevada, Idaho, Oregon, Nebraska, and Vermont; and
2    WHEREAS, Thirteen state government agencies have purchased
3the 8 mg Naloxone nasal spray, including Alabama, Alaska,
4Colorado, Florida, Idaho, Iowa, Kentucky, New Hampshire, Ohio,
5Pennsylvania, Tennessee, Wisconsin, and West Virginia; and
6    WHEREAS, The U.S. Veterans Administration added the 8 mg
7naloxone nasal spray to the National Formulary in November
82021; and
9    WHEREAS, 70% of the number of lives covered by commercial
10insurance in the U.S. can access the 8 mg naloxone nasal spray;
12    WHEREAS, 90% of the number of lives covered by Medicaid
13insurance in the U.S. (40 states) can access the 8 mg naloxone
14nasal spray, including Illinois; and
15    WHEREAS, The current cost of the 4 mg naloxone nasal spray
16is $5.93 per milligram and the 8 mg version is $3.75 mg, or
1736.7 percent less; and
18    WHEREAS, Being good stewards of taxpayer money is a
19priority for the Illinois General Assembly; therefore, be it



HR0981- 4 -LRB102 29409 MST 41402 r

3we strongly urge the Illinois Department of Human Services to
4review the value of expanding its naloxone tool kit to include
5all U.S. Food and Drug Administration-approved versions of
6naloxone to fight the Illinois opioid epidemic; and be it
8    RESOLVED, That suitable copies of this resolution be
9delivered to the Governor of Illinois, the Governor's Chief
10Behavioral Health Officer, the Secretary of the Department of
11Human Services, and the Director of the Division of Substance
12Use, Prevention and Recovery.